Angiotensin Converting Enzyme Inhibitor

Angiotensin Converting Enzyme Inhibitor (CPC catalog code ACEI-001) is a synthetic protease substrate (research reagent) in the protease substrates category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use Angiotensin Converting Enzyme Inhibitor as a reference standard in protease substrates workflows — for example, kinetic (kcat / km) protease characterization and inhibitor screening and ic₅₀ determination. Human clinical evidence is not established.

No. Angiotensin Converting Enzyme Inhibitor is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a protease substrates workflow, Angiotensin Converting Enzyme Inhibitor is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Read on kinetic plate readers at the reporter-appropriate wavelength.

Store lyophilized at −20 °C, protected from light. DMSO stocks stable at −80 °C. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for ACEI-001. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.